MYC and glioblastoma: Following proteomic analysis, we found that SF188 GBM cells treated with alisertib, a clinically validated highly specific AURKA inhibitor, displayed substantial downregulation of the c-Myc protein (Fig. 1a), a master regulator of cell proliferation and metabolism9.